Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naïve hepatocellular ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Moehler, M., Heo, J., Lee, H.C., Tak, W.Y., Chao, Y., Paik, S.W., Yim, H.J., Byun, K.S., Baron, A., Ungerechts, G., Jonker, D., Ruo, L., Cho, M., Kaubisch, A., Wege, H., Merle, P., Ebert, O., Habersetzer, F., Blanc, J.F., Rosmorduc, Olivier, Lencioni, R., Patt, R., Leen, A.M., Foerster, F., Homerin, M., Stojkowitz, N., Lusky, M., Limacher, J.M., Hennequi, M., Gaspar, N., McFadden, B., De Silva, N., Shen, D., Pelusio, A., Kirn, D.H., Breitbach, C.J., Burke, J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682346/
https://www.ncbi.nlm.nih.gov/pubmed/31413923
http://dx.doi.org/10.1080/2162402X.2019.1615817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682346/
https://www.ncbi.nlm.nih.gov/pubmed/31413923
http://dx.doi.org/10.1080/2162402X.2019.1615817

Ejemplares similares